301015 Qingdao Baheal Medical INC.Watchlist
About Qingdao Baheal Medical INC. Company
The company (“Baiyang Pharmaceutical” for short, stock code: 301015) was founded in 2005 and is China's leading health brand commercialization platform. Its business areas cover global brand operation, wholesale distribution and retail of high-quality medical and health products. Focusing on the development strategy of “commercial breakthrough, ecological innovation”, Baiyang Pharmaceutical is guided by optimizing the medical scenario. It is developing and upgrading from a health brand commercialization platform to an ecological BigPharma. Through the integration of scientific and technological innovation resources and incubation capabilities, it is building a platform for transforming scientific research achievements, and continuously cultivating healthcare products and services with independent intellectual property rights. The company's main business is to provide comprehensive commercial solutions for pharmaceutical product manufacturers, including providing brand operation, wholesale distribution and retail of pharmaceutical products, especially product marketing and promotion solutions for branded pharmaceutical manufacturers. Main products or business: Operates brands such as DiQiao series, Bite series, Halle series, Takeda series and Roche series, Cornice, Esnona, Newt Schuma, Atricure, Fuzhenghua, Zisheng; distributes pharmaceuticals, Chinese medicine tablets, medical devices, diagnostic reagents, medical consumables, etc.; sells pharmaceuticals, medical equipment, health food, cosmetics, etc. Corporate honors: Top 50 service enterprises in Shandong in 2021, the first batch of Chinese OTC brand clusters, 2021 Pharmaceutical Industry “13th Five-Year Plan” Enterprise Management Award - Outstanding Growing Enterprises, etc.
Baiyang Pharmaceutical (301015): Focus on CSO platform value release
Incident description The company released its 2023 annual report. In the first half of 2023, it achieved revenue of 3,635 million yuan, a year-on-year decrease of 2.57%; realized net profit of 302 million yuan, an increase of 39.8% over the previous year; and achieved non-net profit deduction 2.
Baiyang Pharmaceutical (301015): Second quarter results exceeded expectations, and the long-term value of brand operation needs to be reassessed
The company released its 2023 mid-year report. 2023H1 achieved revenue of 3,635 million yuan (-2.57% year on year, same below), realized net profit of 302 million yuan (+39.76%), and achieved net profit not attributable to parent
Baiyang Pharmaceutical (301015): Performance growth is in line with expectations, business structure continues to be optimized
Incident: On August 29, 2023, the company released its 2023 annual report. In the first half of 2023, the company achieved operating income of 3.635 billion yuan, a year-on-year decrease of 2.57%; net profit of the return mother was 302 million yuan, the same